Argent Biopharma (AU:RGT) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Argent BioPharma has announced significant progress in the development of CimetrA®, a multi-targeted anti-inflammatory and immunomodulatory formulation aimed at treating complex inflammatory conditions. The drug has evolved through various reformulations since its inception in 2020, removing less effective ingredients and now primarily contains two active components that reduce inflammation and modulate the immune response. CimetrA® has shown promising results in clinical trials, particularly in managing cytokine storms, and could be a vital asset for treating patients with severe inflammatory and immune dysregulation diseases.
For further insights into AU:RGT stock, check out TipRanks’ Stock Analysis page.